GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare’s…
Oscar Health, Inc. (NYSE: OSCR), a healthcare technology leader, announced today that it will expand its offerings in the ACA marketplace in 2025. This move aims to provide more individuals,…
Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part…
Agilent Technologies Inc. (NYSE: A) has unveiled its next-generation Agilent InfinityLab LC Series, featuring the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems,…
Proteintech Genomics, a leader in antibody-based multiplexed solutions for single-cell multiomics, has announced the launch of its MultiPro® Human Discovery Panel. This innovative antibody panel is designed to revolutionize single-cell…
Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today encouraging topline results from the one-year Phase IV ELEVATUM study. This open-label, single-arm trial evaluated Vabysmo® (faricimab-svoa)…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, recently shared encouraging outcomes from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab, a monoclonal antibody aimed at preventing…
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that Health Canada has granted marketing authorization for DAYBUE™ (trofinetide) to treat Rett syndrome in patients aged two and older. This approval, under…
Airway Therapeutics, Inc. has announced the launch of a multinational Phase 3 clinical trial for zelpultide alfa (rhSP-D). This study aims to prevent bronchopulmonary dysplasia (BPD) and mitigate lung injury…
MEDiC Life Sciences, a prominent functional genomics startup in Silicon Valley, has announced a $5M strategic investment from LG and Hanmi Pharmaceutical. This funding precedes MEDiC’s upcoming Series-A round later…
Genentech, part of the Roche Group, shared encouraging two-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society Congress (October 8-12, 2024). This study evaluated the efficacy…
Foundation Medicine, Inc. has announced FDA approval for FoundationOne® Liquid CDx as a companion diagnostic for Itovebi™ (inavolisib) when used with palbociclib (Ibrance®) and fulvestrant. This therapy, developed by Genentech,…